| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8285481 | Parkinsonism & Related Disorders | 2018 | 5 Pages |
Abstract
In people with multiple PD risk factors, those with low CSF DOPA and low CSF DOPAC levels develop clinical disease during follow-up. We suggest that neurochemical biomarkers of central dopamine deficiency identify the disease in a pre-clinical phase.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Ageing
Authors
David S. Goldstein, Courtney Holmes, Grisel J. Lopez, Tianxia Wu, Yehonatan Sharabi,